Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 649

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

Open access
Zhou, Jian, Sun, Hui-Chuan, Wang, Zheng, Cong, Wen-Ming, Wang, Jian-Hua, Zeng, Meng-Su, Yang, Jia-Mei, Bie, Ping, Liu, Lian-Xin, Wen, Tian-Fu, Han, Guo-Hong, Wang, Mao-Qiang, Liu, Rui-Bao, Lu, Li-Gong, Ren, Zheng-Gang, Chen, Min-Shan, Zeng, Zhao-Chong, Liang, Ping, Liang, Chang-Hong, Chen, Min, Yan, Fu-Hua, Wang, Wen-Ping, Ji, Yuan, Cheng, Wen-Wu, Dai, Chao-Liu, Jia, Wei-Dong, Li, Ya-Ming, Li, Ye-Xiong, Liang, Jun, Liu, Tian-Shu, Lv, Guo-Yue, Mao, Yi-Lei, Ren, Wei-Xin, Shi, Hong-Cheng, Wang, Wen-Tao, Wang, Xiao-Ying, Xing, Bao-Cai, Xu, Jian-Ming, Yang, Jian-Yong, Yang, Ye-Fa, Ye, Sheng-Long, Yin, Zheng-Yu, Zhang, Bo-Heng, Zhang, Shui-Jun, Zhou, Wei-Ping, Zhu, Ji-Ye, Liu, Rong, Shi, Ying-Hong, Xiao, Yong-Sheng, Dai, Zhi, Teng, Gao-Jun, Cai, Jian-Qiang, Wang, Wei-Lin, Dong, Jia-Hong, Li, Qiang, Shen, Feng, Qin, Shu-Kui, Fan, Jia·2018·Liver Cancer
DOI 10.1159/000488035
Open this paper in CoChat — free account

Abstract

Background: Hepatocellular carcinoma (HCC) (about 85–90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people. Summary: This guideline presents official recommendations of the National Health and Family Planning Commission of the People’s Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China. The guideline was written by more than 50 experts in the field of HCC in China (including liver surgeons, medical oncologists, hepatologists, interventional radiologists, and diagnostic radiologists) on the basis of recent evidence and expert opinions, balance of benefits and harms, cost-benefit strategies, and other clinical considerations. Key Messages: The guideline presents the Chinese staging system, and recommendations regarding patients with HCC in China to ensure optimum patient outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000488035

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 79 references

Cited by

See all 649

Metadata

Authors
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., Han, G.-H., Wang, M.-Q., Liu, R.-B., Lu, L.-G., Ren, Z.-G., Chen, M.-S., Zeng, Z.-C., Liang, P., Liang, C.-H., Chen, M., Yan, F.-H., Wang, W.-P., Ji, Y., Cheng, W.-W., Dai, C.-L., Jia, W.-D., Li, Y.-M., Li, Y.-X., Liang, J., Liu, T.-S., Lv, G.-Y., Mao, Y.-L., Ren, W.-X., Shi, H.-C., Wang, W.-T., Wang, X.-Y., Xing, B.-C., Xu, J.-M., Yang, J.-Y., Yang, Y.-F., Ye, S.-L., Yin, Z.-Y., Zhang, B.-H., Zhang, S.-J., Zhou, W.-P., Zhu, J.-Y., Liu, R., Shi, Y.-H., Xiao, Y.-S., Dai, Z., Teng, G.-J., Cai, J.-Q., Wang, W.-L., Dong, J.-H., Li, Q., Shen, F., Qin, S.-K., & Fan, J.
Venue
Liver Cancer
Publisher
S. Karger AG
Published
2018
Volume
7
Issue
3
Pages
235-260
ISSN
  • 1664-5553 (ISSN-L)
  • 2235-1795
DOI
10.1159/000488035
OpenAlex
W2808244122
Cited by
649
References
79
FWCI
44.00
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). https://app.cochat.ai/papers/10.1159/000488035
The paper
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., Han, G.-H., Wang, M.-Q., Liu, R.-B., Lu, L.-G., Ren, Z.-G., Chen, M.-S., Zeng, Z.-C., Liang, P., Liang, C.-H., . . . Fan, J. (2018). Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. https://doi.org/10.1159/000488035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.